X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement for manufacturing of the potent IL-1 inhibitor Isunakinra, a recombinant protein for cancer indications.
Lead Product(s): Isunakinra
Therapeutic Area: Oncology Product Name: EBI-005
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Buzzard Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 07, 2021
Details:
SpyBiotech selected 3P Biopharmaceuticals in June 2019 to manufacture a cGMP batch of their virus-like-particle carrier with the goal of completing production in 2021. This carrier will be used to display antigens from different pathogens.
Lead Product(s): VLPs based vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: SpyBiotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 27, 2020
Details:
Toleranzia’s innovative candidate (TOL2) is being developed for the treatment of the autoimmune neuromuscular disease Myasthenia Gravis (MG), an orphan disease, which has a major unmet medical need and a large market potential.
Lead Product(s): TOL2
Therapeutic Area: Immunology Product Name: TOL2
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Toleranzia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
